InCROM has been supporting Phase I studies since 1983. Our know-how and experience gained through the years have made us proficient in supporting even the highly specialized studies such as FIH (First in Human) and FIJ (First in Japanese) studies. No matter the study type, for example, BE (biological equivalence) studies, vaccine studies, pharmacokinetic studies of anticancer drugs and medical narcotics, and even bronchoalveolar lavage (BAL) pharmacokinetic studies which require special techniques, services we provide are highly effective and efficient.
Examples of InCROM Supported Clinical Studies
・First in Human studies
・First in Japanese studies
・Drug-drug Interaction (DDI) studies
・Bioequivalence studies
・Skin Irritation studies (patch test/photopatch test)
・Biopharmaceutical and Biosimilar studies
・Antibodies studies
・Anticancer studies (in healthy adults)
・Bronchoalveolar Lavage (BAL) Pharmacokinetic studies
・Clinical Pharmacology studies in non-Japanese subjects
・Studies in pediatric/elderly subjects
・Vaccine studies
・Narcotic studies
・Investigator-initiated studies
Regulatory approvals in the past 5 years for which the Phase I studies were supported by InCROM
2025: Type 2 diabetes agent (GLP-1 receptor agonist)
2025: Multiple myeloma agent (Cytokine production regulation)
2025: Typhoid Vaccine (Purified Vi polysaccharide typhoid vaccine)
2024: Influenza Vaccine (High-dose influenza HA vaccine)
2024: Meningococcal Vaccine (Quadrivalent meningococcal vaccine)
2024: Pulmonary arterial hypertension agent (Human prostacyclin receptor agonist)
2024: Pneumococcal Vaccine (Precipitated 20-valent Pneumococcal Conjugate Vaccine)
2024: Measles-Rubella Combined Vaccine
2024: COVID-19 Vaccine
2024: Antifungal agent (Voriconazole)
2024: COVID-19 Vaccine
2024: Paroxysmal Nocturnal Haemoglobinuria agent (Iptacopan Hydrochloride Hydrate)
2024: Respiratory Syncytial Virus Infection Vaccine (RSV Vaccine)
2024: Atopic Dermatitis agent (Humanised Anti-Human IL-31RA Monoclonal Antibody)
2024: Breast cancer agent (Oestrogen receptor antagonist)
2023: COVID-19 Vaccine
2023: Prevention of febrile neutropenia (Long-acting G-CSF formulation)
2023: Prostate cancer agent (CYP17 inhibitor)
2022: ALS agent (scavenges free radicals and inhibits oxidative damage to motor neurons and other cells)
2022: Pneumococcal vaccine (precipitated 15-valent pneumococcal vaccine)
2021: Cold syndrome treatments (ibuprofen, ambroxol hydrochloride, etc.)
2021: Anticancer agent (tropomyosin receptor kinase inhibitor)
2021: Cancer cachexia agent (ghrelin-like agonist)
2021: Enterolavage agent
